Takeda Pharmaceutical Company Limited
TAK · NYSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $385,113,000 | $457,800,000 | $533,530,000 | $849,695,000 |
| Short-Term Investments | $20,476,000 | $15,089,000 | $20,174,000 | $25,305,000 |
| Receivables | $725,254,000 | $697,610,000 | $681,694,000 | $724,378,000 |
| Inventory | $1,217,349,000 | $1,209,869,000 | $986,457,000 | $853,167,000 |
| Other Curr. Assets | $173,000,000 | $178,212,000 | $176,101,000 | $141,097,000 |
| Total Curr. Assets | $2,521,192,000 | $2,558,580,000 | $2,397,956,000 | $2,593,642,000 |
| Property Plant & Equip (Net) | $1,968,209,000 | $1,989,777,000 | $1,691,229,000 | $1,582,800,000 |
| Goodwill | $5,324,430,000 | $5,410,067,000 | $4,790,723,000 | $4,407,749,000 |
| Intangibles | $3,631,560,000 | $4,274,682,000 | $4,269,657,000 | $3,818,544,000 |
| Long-Term Investments | $361,926,000 | $430,608,000 | $378,857,000 | $330,133,000 |
| Tax Assets | $370,745,000 | $393,865,000 | $366,003,000 | $362,539,000 |
| Other NC Assets | $70,282,000 | $51,214,000 | $63,325,000 | $82,611,000 |
| Total NC Assets | $11,727,152,000 | $12,550,214,000 | $11,559,794,000 | $10,584,377,000 |
| Other Assets | $0 | -$2,000 | $0 | -$1,000 |
| Total Assets | $14,248,344,000 | $15,108,792,000 | $13,957,750,000 | $13,178,018,000 |
| Liabilities | – | – | – | – |
| Payables | $308,450,000 | $319,955,000 | $307,453,000 | $295,934,000 |
| Short-Term Debt | $548,939,000 | $367,251,000 | $339,600,000 | $203,993,000 |
| Tax Payable | $0 | $109,906,000 | $232,377,000 | $200,918,000 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $1,649,132,000 | $1,515,991,000 | $1,602,510,000 | $1,444,885,000 |
| Total Curr. Liab. | $2,506,521,000 | $2,313,103,000 | $2,481,940,000 | $2,145,730,000 |
| LT Debt | $3,966,326,000 | $4,476,501,000 | $4,042,741,000 | $4,141,418,000 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $35,153,000 | $113,777,000 | $270,620,000 | $451,511,000 |
| Other NC Liab. | $804,365,000 | $931,406,000 | $807,778,000 | $755,836,000 |
| Total NC Liab. | $4,805,844,000 | $5,521,684,000 | $5,121,139,000 | $5,348,765,000 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $7,312,365,000 | $7,834,787,000 | $7,603,079,000 | $7,494,495,000 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1,694,685,000 | $1,676,596,000 | $1,676,345,000 | $1,676,263,000 |
| Retained Earnings | $1,187,586,000 | $1,391,203,000 | $1,541,146,000 | $1,479,716,000 |
| AOCI | $2,351,915,000 | $2,509,310,000 | $1,508,119,000 | $934,173,000 |
| Other Equity | $1,700,898,000 | $1,696,155,000 | $1,628,512,000 | $1,592,867,000 |
| Total Equity | $6,935,084,000 | $7,273,264,000 | $6,354,122,000 | $5,683,019,000 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $895,000 | $741,000 | $549,000 | $504,000 |
| Total Liab. & Tot. Equity | $14,248,344,000 | $15,108,792,000 | $13,957,750,000 | $13,178,018,000 |
| Net Debt | $4,130,152,000 | $4,385,952,000 | $3,848,811,000 | $3,495,716,000 |